Search
Tonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalIt is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
NN344
go.drugbank.com/drugs/DB05115ExperimentalNN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Eliapixant
go.drugbank.com/drugs/DB21465InvestigationalEliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive … The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.
Mubodina
go.drugbank.com/drugs/DB17616ExperimentalIt was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome. … Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.
Synonyms: Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1Etidocaine
go.drugbank.com/drugs/DB08987ApprovedIt is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.
Brolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]
Inetetamab
go.drugbank.com/drugs/DB17457InvestigationalIt differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.